The Variation of Psychopharmacological Prescription Rates for People With Autism Spectrum Disorder (ASD) in 30 Countries

Autism Research

Volumn 7, Issue 5, 2014, Pages 543-554

  Wong, Angel Y S ^a   Hsia, Yingfen ^a,d   Chan, Esther W ^a   Murphy, Declan G M ^b   Simonoff, Emily ^b   Buitelaar, Jan K ^c   Wong, Ian C K ^a,d  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c RADBOUD UNIVERSITY   (Netherlands)

^d UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Epidemiology; Gross Domestic Product; Multinational study; Psychopharmacology

Indexed keywords

AFRICA; ASIA; CENTRAL AMERICA; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CLINICAL PRACTICE; COMORBIDITY; DRUG DATABASE; ECONOMICS; EUROPE; GROSS NATIONAL PRODUCT; HUMAN; INCOME; INTERNATIONAL COOPERATION; MENTAL DISORDERS; PACIFIC ISLANDS; PSYCHOPHARMACOLOGY; SOCIOECONOMICS; SOUTH AMERICA; STATISTICS AND NUMERICAL DATA;

AFRICA; ASIA; CENTRAL AMERICA; CHILD DEVELOPMENT DISORDERS, PERVASIVE; COMORBIDITY; DATABASES, PHARMACEUTICAL; EUROPE; GROSS DOMESTIC PRODUCT; HUMANS; INCOME; INTERNATIONALITY; MENTAL DISORDERS; OCEANIA; PHYSICIAN'S PRACTICE PATTERNS; PSYCHOPHARMACOLOGY; SOCIOECONOMIC FACTORS; SOUTH AMERICA;

EID: 84931471107     PISSN: 19393792     EISSN: 19393806     Source Type: Journal    
DOI: 10.1002/aur.1391     Document Type: Article

References (42)

1. Almandil, N.B., Liu, Y., Murray, M.L., Besag, F.M., Aitchison, K.J., & Wong, I.C. (2013). Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: A systematic review and meta-analysis. Paediatric Drugs, 15, 139-150.
2. Almandil, N.B., & Wong, I.C. (2011). Review on the current use of antipsychotic drugs in children and adolescents. Archives of Disease in Childhood. Education and Practice Edition, 96, 192-196.
3. American Psychiatric Association. (1994). Diagnostic and statistical manual of mental diseases (DSM-IV) (4th ed.). Washington, DC: American Psychiatric Publishing.
4. Baird, G., Simonoff, E., Pickles, A., Chandler, S., Loucas, T., etal. (2006). Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: The Special Needs and Autism Project (SNAP). Lancet, 368, 210-215.
5. Balkrishnan, R., Phatak, H., Gleim, G., & Karve, S. (2009). Assessment of the use of angiotensin receptor blockers in major European markets among paediatric population for treating essential hypertension. Journal of Human Hypertension, 23, 420-425.
6. Bradley, E., & Bolton, P. (2006). Episodic psychiatric disorders in teenagers with learning disabilities with and without autism. The British Journal of Psychiatry: The Journal of Mental Science, 189, 361-366.
7. Cadman, T., Eklund, H., Howley, D., Hayward, H., Clarke, H., etal. (2012). Caregiver burden as people with autism spectrum disorder and attention-deficit/hyperactivity disorder transition into adolescence and adulthood in the United Kingdom. Journal of the American Academy of Child and Adolescent Psychiatry, 51, 879-888.
8. Carbone, P.S., Farley, M., & Do, T.D. (2010). Primary care for children with autism. American Family Physician, 81, 453-460.
9. Coury, D.L., Anagnostou, E., Manning-Courtney, P., Reynolds, A., Cole, L., etal. (2012). Use of psychotropic medication in children and adolescents with autism spectrum disorders. Pediatrics, 130(Suppl. 2), S69-S76.
10. Elsabbagh, M., Divan, G., Koh, Y.J., Kim, Y.S., Kauchali, S., etal. (2012). Global prevalence of autism and other pervasive developmental disorders. Autism Research: Official Journal of the International Society for Autism Research, 5, 160-179.
11. European Medicines Agency (EMA). (2007). Assessment of the paediatric needs psychiatry. Retrieved September 2, 2013 from http://www.ema.europa.eu/docs/en_GB/document_library/Other/2009/10/WC500004046.pdf
12. Frazier, T.W., Shattuck, P.T., Narendorf, S.C., Cooper, B.P., Wagner, M., & Spitznagel, E.L. (2011). Prevalence and correlates of psychotropic medication use in adolescents with an autism spectrum disorder with and without caregiver-reported attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 21, 571-579.
13. Hollander, E., Phillips, A.T., & Yeh, C.C. (2003). Targeted treatments for symptom domains in child and adolescent autism. Lancet, 362, 732-734.
14. Hsia, Y., Wong, A.Y., Murphy, D.G.M., Simonoff, E., Buitelaar, J.K., & Wong, I.C. (2014). Psychopharmacological prescriptions for people with autistic spectrum disorder (ASD): A multinational study. Psychopharmacology, 231, 999-1009.
15. Kogan, M.D., Blumberg, S.J., Schieve, L.A., Boyle, C.A., Perrin, J.M., etal. (2009). Prevalence of parent-reported diagnosis of autism spectrum disorder among children in the US, 2007. Pediatrics, 124, 1395-1403.
16. Livermore, D.M., Reynolds, R., Stephens, P., Duckworth, G., Felmingham, D., etal. (2006). Trends in penicillin and macrolide resistance among pneumococci in the UK and the Republic of Ireland in relation to antibiotic sales to pharmacies and dispensing doctors. International Journal of Antimicrobial Agents, 28, 273-279.
17. Lund, C., Tomlinson, M., De Silva, M., Fekadu, A., Shidhaye, R., etal. (2012). PRIME: A programme to reduce the treatment gap for mental disorders in five low- and middle-income countries. PLoS Medicine, 9, e1001359.
18. MacArthur, G., & The Academy of Medical Sciences. (2008). Challenges and priorities for global mental health research in low- and middle-income countries: Symposium report. Retrieved July 4, 2013 from http://www.eldis.org/go/topics/resource-guides/health-systems/governance-and-health&id=43964&type=Document#.UdUtFPk9Fio
19. MacNeil, B.M., Lopes, V.A., & Minnes, P.M. (2009). Anxiety in children and adolescents with autism spectrum disorders. Research in Autism Spectrum Disorders, 3, 1-21.
20. Mandell, D.S., Morales, K.H., Marcus, S.C., Stahmer, A.C., Doshi, J., & Polsky, D.E. (2008). Psychotropic medication use among medicaid-enrolled children with autism spectrum disorders. Pediatrics, 121, e441-e448.
21. Marcus, R.N., Owen, R., Kamen, L., Manos, G., McQuade, R.D., etal. (2009). A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 48, 1110-1119.
22. Matson, J.L., & Neal, D. (2009). Seizures and epilepsy and their relationship to autism spectrum disorders. Research in Autism Spectrum Disorders, 3, 999-1005.
23. McPheeters, M.L., Warren, Z., Sathe, N., Bruzek, J.L., Krishnaswami, S., etal. (2011). A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics, 127, e1312-e1321.
24. Murray, M.L., Hsia, Y., Glaser, K., Simonoff, E., Murphy, D.G., etal. (2014). Pharmacological treatments prescribed to people with autism spectrum disorder (ASD) in primary health care. Psychopharmacology, 231, 1011-1021.
25. Myers, S.M., Johnson, C.P., & American Academy of Pediatrics Council on Children with Disabilities. (2007). Management of children with autism spectrum disorders. Pediatrics, 120, 1162-1182.
26. Owen, R., Sikich, L., Marcus, R.N., Corey-isle, P., Manos, G., etal. (2009). Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics, 124, 1533-1540.
27. Rani, F., Murray, M.L., Byrne, P.J., & Wong, I.C. (2008). Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics, 121, 1002-1009.
28. Rani, F.A., Byrne, P., Cranswick, N., Murray, M.L., & Wong, I.C. (2011). Mortality in children and adolescents prescribed antipsychotic medication: A retrospective cohort study using the UK general practice research database. Drug Safety: An International Journal of Medical Toxicology and Drug Experience, 34, 773-781.
29. Rani, F.A., Byrne, P.J., Murray, M.L., Carter, P., & Wong, I.C. (2009). Paediatric atypical antipsychotic monitoring safety (PAMS) study: Pilot study in children and adolescents in secondary- and tertiary-care settings. Drug Safety: An International Journal of Medical Toxicology and Drug Experience, 32, 325-333.
30. Rosenberg, R.E., Mandell, D.S., Farmer, J.E., Law, J.K., Marvin, A.R., & Law, P.A. (2010). Psychotropic medication use among children with autism spectrum disorders enrolled in a national registry, 2007-2008. Journal of Autism and Developmental Disorders, 40, 342-351.
31. Saxena, S., Sharan, P., & Saraceno, B. (2003). Budget and financing of mental health services: Baseline information on 89 countries from WHO's project atlas. The Journal of Mental Health Policy and Economics, 6, 135-143.
32. Shea, S., Turgay, A., Carroll, A., Schulz, M., Orlik, H., etal. (2004). Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics, 114, e634-e641.
33. Simonoff, E., Pickles, A., Charman, T., Chandler, S., Loucas, T., & Baird, G. (2008). Psychiatric disorders in children with autism spectrum disorders: Prevalence, comorbidity, and associated factors in a population-derived sample. Journal of the American Academy of Child and Adolescent Psychiatry, 47, 921-929.
34. Souders, M.C., Mason, T.B., Valladares, O., Bucan, M., Levy, S.E., etal. (2009). Sleep behaviors and sleep quality in children with autism spectrum disorders. Sleep, 32, 1566-1578.
35. Star, K., Iessa, N., Almandil, N.B., Wilton, L., Curran, S., etal. (2012). Rhabdomyolysis reported for children and adolescents treated with antipsychotic medicines: A case series analysis. Journal of Child and Adolescent Psychopharmacology, 22, 440-451.
36. Wang, P.S., Aguilar-Gaxiola, S., Alonso, J., Angermeyer, M.C., Borges, G., etal. (2007). Use of mental health services for anxiety, mood, and substance disorders in 17 countries in the WHO world mental health surveys. Lancet, 370, 841-850.
37. Williams, J.G., Higgins, J.P., & Brayne, C.E. (2006). Systematic review of prevalence studies of autism spectrum disorders. Archives of Disease in Childhood, 91, 8-15.
38. Wong, I.C., & Murray, M.L. (2005). The potential of UK clinical databases in enhancing paediatric medication research. British Journal of Clinical Pharmacology, 59, 750-755.
39. Wong, I.C., Murray, M.L., Camilleri-Novak, D., & Stephens, P. (2004). Increased prescribing trends of paediatric psychotropic medications. Archives of Disease in Childhood, 89, 1131-1132.
40. World Health Organization (WHO). (2012). The ICD-10 Classification of Mental and Behavioural Disorders: Clinical descriptions and diagnostic guidelines. Retrieved May 24, 2013 from http://www.who.int/classifications/icd/en/bluebook.pdf
41. World Health Organization (WHO). (2013). Application for inclusion to the 19th expert committee on the selection and use of essential medicines: Risperidone. Retrieved August 25, 2013 from http://www.who.int/selection_medicines/committees/expert/19/applications/Risperidone_24_A_Ad_Final.pdf
42. Zito, J.M., Safer, D.J., de Jong-van den Berg, L.T., Janhsen, K., Fegert, J.M., etal. (2008). A three-country comparison of psychotropic medication prevalence in youth. Child and Adolescent Psychiatry and Mental Health, 2, 1-8.